Retrovirus-mediated gene therapy for human hepatocellular carcinoma transplanted in athymic mice.

Ueki,T; Nakata,K; Mawatari,F; Tsuruta,S; Ido,A; Ishikawa,H; Nakao,K; Kato,Y; Ishii,N; Eguchi,K

doi:10.3892/ijmm.1.4.671

Retrovirus-mediated gene therapy for human hepatocellular carcinoma transplanted in athymic mice.

Authors:
- T Ueki
- K Nakata
- F Mawatari
- S Tsuruta
- A Ido
- H Ishikawa
- K Nakao
- Y Kato
- N Ishii
- K Eguchi
View Affiliations

Affiliations: The First Department of Internal Medicine, Nagasaki University School of Medicine, Nagasaki 852, Japan.
Published online on: April 1, 1998 https://doi.org/10.3892/ijmm.1.4.671
Pages: 671-676

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gene therapy using a retrovirus vector carrying herpes simplex virus thymidine kinase gene under the control of the 0.3-kb human alpha-fetoprotein (AFP) gene promoter (LNAF0.3TK virus) in combination with ganciclovir (GCV) treatment was performed in athymic mice harboring AFP-producing HuH-7 human hepatoma cells. GCV treatment resulted in pronounced growth inhibition of the virus-infected HuH-7 xenograft in mice, but did not affect growth of the parental xenograft. These results indicate that the AFP gene promoter sequence allows enough therapeutic gene expression to induce the GCV-mediated cytotoxicity in vivo in AFP-producing human hepatoma cells.